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Abstract
Objective—Thrombocytopenia (TCP<150 × 103 cells/mm3) has emerged as a relevant factor in 
the clinical course of HIV. However, the mechanisms mediating such observations have not been 
well characterized, limiting the possibility of creating targeted interventions. Notably, platelets are 
the storage and transporter system for serotonin and Brain derived neurotrophic factor (BDNF), 
which recent laboratory studies associated with viral replication and lymphocyte survival. Thus, 
we posit that (1) TCP will be associated with reduced levels of BDNF and serotonin (2) That these 
alterations will lead to poor viro-immune responses to antiretroviral therapy.
Methods—To achieve this goal, a total of 400 people living with HIV were consecutively 
enrolled to characterize the frequency of thrombocytopenia in hazardous and non-hazardous 
alcohol user populations in the HAART era. Then, participants underwent immune and laboratory 
assessments, to determine if TCP was associated with alterations in serotonin (5-HT) and brain 
derived neurotrophic factor (BDNF).
Results—The prevalence of thrombocytopenia in this antiretroviral treated cohort was 14%. 
Rates were significantly higher in the heavy alcohol users, HAU versus the non HAU group 
(Heavy: 25% versus HAU: 15% versusnon-HAU: 10%). Multivariate model analyses indicated 
that having TCP, low BDNF levels (<5000 pg/ml), and number of drinks per day were predictors 
of serotonin levels. PLWH with TCP had about 2-fold lower PPP-BDNFlevels (5037.4 ± 381 vs. 
9137.5 ± 7062 pg/ml p=0.0001). Other significant predictors of BDNF levels at the last visit 
included receiving selective serotonin reuptake inhibitors and PPP serotonin levels. Multivariate 
analyses also confirmed that altered serotonin levels were associated withhigh viral loadsboth low 
CD4 cell counts.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Conclusions—Thrombocytopenia is a relatively frequent complication of HIV, andis 
particularly prevalent among hazardous alcohol users (HAU). These findings suggest that TCP is 
associated with altered levels of BDNF and serotonin, suggesting that they may be the bridge 
linking TCP and poor viro-immune responses observed in this group. These results could have 
important clinical and therapeutic implications.
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Introduction
Thrombocytopenia (TCP: a platelet count of less than 150,000 per microliter), is a common 
hematological complication which affects a sizable proportion of people living with HIV 
(PLWH) [1-6]. Although TCP causes are multifactorial, given the direct effect of HIV in 
platelet destruction, it was expected that this problem would no-longer exist with the 
introduction of antiretroviral therapy. However, thrombocytopenia is still present in 
approximately 15% of the cases [1-6]. Our prior study indicates that alcohol negatively 
impacts platelets, and may be an important contributing factor to TCP persistence [6,7].
Although frequently overseen, TCP hasbeen associated with increased morbidity and 
mortality [1-4]. Nevertheless, the mechanism mediating this association is uncertain, 
highlighting the need for further research. In this regards, it needs to be emphasized that the 
role of platelets has expandedfrom hemostasis to inflammation, and host defense [8,9]. In 
fact, confluent pieces of evidence indicate that platelets share structural and functional 
similarities with granulocytes, known to participate in antimicrobial host defense. Platelets 
have the ability to internalize the HIV, suggesting a potential role of platelets in the immune 
response [8,9]. Notably, platelets also contain a number of broad spectrum antimicrobial 
peptides, RANTES and MIP-1 that can enact as HIV-suppressive factors [8,9].
Circulating platelets may enact as a transportation system for serotonin (5-
hydroxytryptamine, 5-HT) [10-14]. Serotonin is aneuromodulator, stored within the dense 
granules of the platelets, that only becomes physiologically active upon platelet 
degranulation [10-11,14]. Platelets are also a source of brain derived neurotrophic factor 
(BDNF), for which an auto/paracrine feedback loop regulation with serotonin exist. Notably, 
recent studies have uncovered important roles for serotonin in the periphery, including liver 
regeneration, and support to the immune response [14]. Laboratory experiments have 
demonstrated that serotonin is needed for T cell proliferation [15]. Monocytes/macrophages 
which are involved in the control of HIV also express serotonin receptors. Relevant for our 
proposal, studies also suggest that 5-HT can inhibit the replication of HIV-1 in primary 
culture of human macrophages through its action on 5-HT1A receptors [16]. Therefore, it is 
of great interest to assess among PLWH the impact of TCP and serotonin in the periphery. 
As depicted in Figure 1, we postulate a priori that thrombocytopenia will be accompanied 
with BDNF and serotonin disorders that may impact the immune response as well viral 
control.
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Methods
Sampling
The Platelets Mediating Alcohol and HIV Damage Study (PADS) is a large, single-site 
multi-ethnic cohort, consisting of 400 PLWH, who are at least 18 years old and under 
regular care at Miami’s primary open-access public health system. Participants were 
recruited via flyers, personal contact at the clinics, or called our office to schedule an 
appointment. Our choice of PLWH in an open-access public health system with standard 
treatment protocols was purposefully designed to minimize social, medical, and treatment 
inequalities. To reduce the confounding effects of illicit drug use, the DSM-IV-TR 
questionnaire was applied, and those who were dependent on drugs or injecting illicit 
psychoactive substances were excluded.
Non-ambulatory patients, and those presenting with major medical co-morbidities, such as 
CNS opportunistic infection, head injury, tumors, major psychiatricdisease, developmental 
disorders, severe malnutrition, chronic renal failure, intestinal pathology, thyroid problems, 
cardiovascular or immune-based disease, (i.e., malignancies, autoimmune diseases, or 
arthritis) were excluded. In addition, based on medical records, participants who had 
cirrhosisor active viral hepatitis were not eligible. Otherwise, the subject was enrolled.
PADS were approved by the central governing Institutional Review Boards at Florida 
International University and University of Miami. The study was conducted according to the 
principles expressed in the Declaration of Helsinki. Those participants who provided written 
informed consent and a signed medical release form were consecutively enrolled, and 
followed over a period of six months.
Alcohol use
At each visit, PLWH reported alcohol intake in the past six months, using two standardized 
and validated brief screening questionnaires: the Alcohol Use Disorders Identification Test 
(AUDIT), and the Alcohol Dependence Scale (ADS) [17-19]. Alcohol consumption scores 
were computed by averaging cross products of quantity and frequency of beer/wine and hard 
liquor reported on the AUDIT and ADS responses. Then, based on the National Institute of 
Alcohol Abuse and Alcoholism guidelines criteria, men who reported >14 drinks/week or 
>4 drinks in one day, and women>7 drinks/week or >3 drinks in one day were classified as 
HAU, while those who reported fewer drinks were categorized as non-HAU [19].
Platelet counts, brain derived neurotrophic factor, and serotonin
Blood was drawn in fasting subjects in order to best evaluate immunological, 
andhematological parameters. Cell blood counts were obtained using the cell-Dyn 4000, a 
multi-parameter automatedhematology analyzer system, recommended for specimens with 
low or high plateletconcentrations. Thrombocytopenia (absolute thrombocytopenia) was 
defined as platelet counts below 150 × 103 cells/mm3. Subjects with PLT counts above this 
threshold served as the reference group.
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Platelet-poor plasma (PPP) was obtained, as it is commonly used to measure platelet 
associated factors. To obtain platelet-poor plasma, blood samples collected in EDTA-coated 
tubes (plasma) (BD Diagnostic Systems, NJ, USA) were stored in ice. Plasma was separated 
by centrifugation at 40°C for 15 min at 1,500 × g. This plasma was again re-centrifuged at 
10,000 × g and aliquots of PPP were stored in polypropylene tubes at -80°C until assayed.
Quantification of serotonin (5-HT) was achieved using a commercially available enzyme-
linked immune sorbent assay (ELISA), and procedures were followed asper the 
manufacturer’s instructions (GenWay Biotech, San Diego, CA). PPP BDNF levels were 
measuredusing an ELISA kit (R&D System), according to the manufacturer’s instructions. 
Briefly, 50 μl of standards and 20 fold diluted samples were pipetted into wells of 96-well 
immune plates. An enzyme-linked monoclonal antibody specific for BDNF was added to the 
wells. The maximum detectable dose of BDNF is typically 4,000 pg/mL, but samples were 
further diluted because the majority of study participants had values above 4,000 pg/ml.
Viral load and CD4 cell outcomes
Flow cytometry was used to quantify the percentage and absolute numbers of T lymphocyte 
sub populationsCD3+/CD4+ and CD3+/CD8. In addition, HIV viral burden was quantified 
using the Amplicor HIV monitor test (Roche Diagnostic System). Virological success was 
defined as achieving undetectable viral loads.
Covariates
Upon entry into the study, and using standardized questionnaires, sociodemographic data, 
medical history, HIV- related variables including years since HIV diagnosis, AIDS 
diagnosis, antiretroviral regimen and duration, adherence, treatment for mood disorders, and 
liver-related testswere obtained.
Statistical analyses
A sample size calculation estimated that current sample size would provide 80% power to 
detect differences between platelet groups (alpha of 0.05). The data were analyzed using 
SAS version 8 and SPSS version 11, and p values<0.05 were considered to be statistically 
significant. All variables were examined for skewness, and when necessary were log-
transformed (to base 10; such as viral load). Following descriptive statistical analyses, 
baseline demographic, clinical, BDNF and serotonin differences between the two platelet 
groups were compared using Student’s t test and one-way analysis of variance. Correlations 
among the main variables of interest wereexamined with Pearson’s coefficients.
Univariate, bivariate and multivariate analyses were used to calculate odds ratios (OR) and 
95% confidenceintervals (CI). Logistic regression analyses were used to evaluate the effects 
ofalcohol (hazardous vs. non-hazardous), and thrombocytopenia (thrombocytopenia vs. 
normal platelet counts) on BDNF and serotonin levels, while controlling for age, gender, 
race, and receiving therapy for neuropsychological disorders. Potential predictors of 
virological and immune responses (i.e., gender, race/ethnicity, CDC status, druguse, and 
body mass index) were selected on the basis of the HIV medical literature, andwere added to 
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the model. Non-significant variables (p≥0.05) were removed, beginningwith the least 
significant variable, until the final full model was achieved.
Results
Study population characteristics
Most (80%) of the individuals in the study had normal platelets, hemoglobin, andhematocrit 
measurements, and no significant differences in mean hemoglobin, hematocrit, or proportion 
of anemia were observed between patients with thrombocytopenia (13.2 ± 2.0) and those 
with normal platelet counts (13.0 ± 1.9 g/dl).
As depicted in Table 1, thrombocytopenic patients were more likely to be males(22% vs. 
7%, p=0.0001). They also tended to have higher AST (p=0.06), but did not differ in ALT 
values. HIV-associated thrombocytopenia occurred in patients from all major risk groups, 
including those exposed via homosexual or heterosexual contact, injection drug use, 
transfusions and those with multiple risks. Yet, additional analyses indicated that 
thrombocytopenic patients significantly differed in their patterns of alcohol consumption, 
when compared to patients with normal platelet counts. Subjects with thrombocytopenia 
consumed in average more drinks per week. Additional analyses indicated that they were 
more likely to be hazardous alcohol users (Odds Ratio: OR=2.4, 95% CI: 1.2-7.2, p=0.05). 
They also had slightly more years drinking (2 years), though differences did not reach 
statistical significance. Notably, groups did not differ in age or socioeconomic status. 
Groups were similar in the number of years living with HIV, type of treatment received and 
the proportion of subjects being adherent to the prescribed regimens.
Thrombocytopenia and BDNF
To evaluate whether there was a relationship between platelet counts and serotonin levels we 
started by running correlations. Analyses revealed a significant correlation between platelet 
counts and 5HT levels (r=0.14, p=0.01). Among PLWH, a main effect was observed in the 
platelet group, with subjects with normal platelet counts having significantly higher 
serotonin levels were significantly reduced in PLWH with TCP, as compared to those with 
low platelet counts (89.4 ± 5.4 vs.45.9 ± 7.6 ng/mL, p=0.001). Group differences were 
substantial; mean serotonin levels of the TCP groupwere 52% lower than the control group. 
Serotonin levels tended to differby gender among PLWH, with women exhibiting the 
highest levels (93.6 ± 7.8 vs. 76.9 ± 5.5 ng/ml, p=0.07).
Serotonin and treatments
Given that antidepressant treatment mechanisms of action have been linked withregulations 
of serotonin levels, we investigatedif these treatments may overcome the observed changes. 
Levels of PPP serotonin were lower in subjects receiving selective serotonin 
reuptakeinhibitors (SSRIs), (62.4 ± 9.7 vs. 88.6 ± 5.0 ng/mLp=0.02). Viral loads were 
notably lower in patients in the SSRI group when compared to the non-SSRI group (2.5 ± 
1.2 vs. 2.8 ± 1.3 viral log, p=0.04).
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Based on prior studies indicating that HIV directly can affect serotonin, we examined the 
impact of antiretroviral treatment on serotonin levels [20]. In accord with prior studies, 
differences in PPP serotonin levels were found between patients who were receiving 
antiretrovirals and achieved viral suppression and those who did not (undetectable: 98.0 ± 
6.6 vs. 68.9 ± 6 ng/mL, p=0.001).
Longitudinal analyses
When a longitudinal analysis was performed, platelet status was a significant predictor of 
serotoninandBDNF. Serotonin did not significantly change during the length of the study in 
TCP subjects, yet among those with normal platelet counts a decrease in both PPP serotonin 
(-31 ± 7.7 ng/mL, p=0.0001) and BNDF (-1423 ± 754, pg/ml, p=0.06) was observed during 
the 6 month follow-up.
In a multiple regression model (see Table 2), with serotonin levels at the last visit as the 
dependent variable, there were no significant contributions from gender (p=0.61), race 
(p=0.38), BMI, or receiving antidepressants (p=0.1). Yet, platelet count below 150 ×103 
cells/mm3 (p=0.05), BDNF below 5000 pg/ml (p=0.0001), and number of drinks per day 
were significant predictors (p=0.008).
Clinical relevance
To evaluate whether there was a correlation between platelet counts and viro-immune status, 
we first compared the mean CD4 cell counts and viral loads of patients with and without 
TCP. Subjects with TCP had significantly lower CD4 counts both at baseline (307 ± 237 vs.
450 ± 284 cell counts, p=0.001); and at follow-up(275 ± 230 vs.426 ± 275 cell counts, 
p=0.005). Individuals with TCP also had higher viral loads at baseline (3.3 ± 1.5 vs. 2.6 ± 
1.3 viral load log,p=0.02). Viral loads at the follow-up assessmentwere also higher (3.4 ± 
1.6 vs. 2.7 ± 1.3 viral load log, p=0.05).
Finally, using Linear Regression analyses, we investigated whether differential CD4 and 
viral load responses observed in people receiving antiretrovirals may be associated with the 
status of serotonin and TCP. Multivariate logistic regressions were fitted to predict the 
probability of having less than 500 CD4 cell counts at the last visit by considering the 
following as explanatory variables: age, gender, race, route of transmission, time with HIV 
infection, time receiving antiretroviral therapy, antiretrovirals used at baseline, adherence, 
viral load, alcohol use, BMI, albumin, and liver function (Tables 3 and 4). The first 
regression model examined the predictors of CD4 cell counts above 500 at the last visit, and 
the R2 was 0.29, indicating that the model predicted approximately 29% of the variance in 
the cell counts (In the multivariate analysis (Table 4), total drinks per week and gender were 
the only significant predictors of CD4 cell countsat the last visit.
The second model focuses on viral load suppression at the last visit. The R2 of the model 
was 0.23. Analyses confirmed that TCP, age, baseline CD4 counts, serotonin levels and 
SSRI are important predictors of successful suppression of HIV.
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Discussion
First, our data demonstrated that having TCP is still common (15-25%) in our urban HIV 
population in South Florida. TCP occurs indistinctively in those exposed via injection drug 
use, blood transfusion, or by homosexual or heterosexual contact. Yet it climbs as high as 
25% among heavy alcohol users. In accord with our initial hypothesis, analyses revealed 
positive associations between TCP and abnormal serotonin and BDNF values,indicating that 
we should redirect our concerns to ensure that PLWH are maintaining a normal platelet 
count. Regression analysis revealed that alterations in serotonin levels were significantly 
associated with antiviral therapy outcomes. These results have several public health and 
clinical implications. The data has provided first time evidence of the mechanism mediating 
the observed relationship between TCP and poor clinical prognosis. These findings 
underscore the need for treatment of hematological and mood disorders if antiretroviral 
therapy is to be fully successful. This studyhas also set the stage for new clinical trials 
aiming to improve platelet counts, given the limited therapeutic options currently available 
for PLWH with these hematological disorders. Though we focused on virological and 
immune responses, given BDNF and 5HT critical roles on cognitive and mood homeostasis 
[14,15], the need to closely follow-up TCP subjects is clear.
Prevalence estimates of thrombocytopenia (<150000 platelets/l) in the literature varied 
greatly (10-30%); however, after the introduction of antiretroviral therapy, prevalences have 
been generally above 10% [1-6]. Nevertheless, in our urban HIV population in South Florida 
and despite having received therapy, TCP was present in 15% of the sample. In other words, 
if worldwide there are 35.3 million people living with HIV [21], then between 4-6 million of 
them could develop TCP. Such excessive rates should receive more attention, given TCP’s 
confirmed role on clinical morbidity and mortality in PLWH [1-6]. Although many scientists 
and clinicians are only linking TCP with vascular problems, our analyses confirmed that 
TCP was strongly associated with uncontrolled HIV replication. Analyses also highlighted 
the relevance of platelets in achieving high CD4 cell counts and a stronger overall on the 
immune response. However, much work still needs to be performed to identify precisely 
what role platelets have in the HIV disease beyond the cardiovascular system.
We found serotonin deficiencies observed amongsubjects with thrombocytopenia. Indeed,in 
the multivariate model BDNF concentrations, TCP and high viral loads were the only 
predictors of serotonin levels at the last visit. The concomitant presence of 
thrombocytopenia and alcohol could be reducing the supply of tryptophan and serotonin 
production [22]. In addition, BDNF depletions can be compromising the function and 
growth of serotonergic neurons [23]. Beyond HIV specific risks, many neuropsychological 
conditions have a serotonergic component, and therefore it could be expected that these 
subjects will be at risk of developing these types of disorders [15]. Serotonin and platelet 
growth factors are also needed to promote liver regeneration, a response that will be limited 
in alcohol users and older subjects [15]. Accordingly, correcting platelet, serotonin and 
BDNF alterations is of medical importance, particularly as this population ages.
Serotonin’s role in viral control deserves special consideration. We discovered differences in 
PPP serotonin levels between subjects who achieved viral suppression and those who did 
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not. The decreased levels of serotonin among TCP subjects are of great concern, given 
recent studies demonstrating in vitro that 5-HT is able to decrease HIV infection via its 
action on 5-HT1A receptors [17,24]. In addition, serotonin decreased the expression of the 
HIV co-receptor CCR5, and increased MIP-1α [17,24]. Notably, subjects taking SSRIs 
displayed significantly lower viral load levels, suggesting that SSRIs, by increasing 
extracellular concentrations of serotonin may suppress HIV infectivity and replication. 
These findings also warrant intervention studies to determine if other drugs that target 
serotonin and BDNF maybe useful as supportive therapy.
Nevertheless, our results should be interpreted in the context of the study limitations: First, a 
short time follow-up that reduced our capacity to perform more detail analyses. Second, the 
study designdid not allow to establish causality, neither to generalize study findings as we 
primarily focusedon alcohol. Therefore, additional studies are needed to replicate our 
findings among subjects with viral hepatitis and with drug abusers. Nonetheless, these 
results may have important research, clinical, and therapeutic implications. They improve 
our understanding of the relevance of platelets in the neuro-immune systems. By identifying 
those HIV-infected individuals at risk for ART failures, such as those with 
thrombocytopenia, alcohol abuse, and with BDNF and serotonin deficits the study may 
permit early clinical follow-ups and interventions. Findings may also guide the development 
of future therapies.
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Figure 1. 
Proposed Model.
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Table 1
Sample Characteristics by TCP Group.
Variable Non-TCP (N=80) TCP (N=320) P value
Age 43 ± 6.7 42.6 ± 7 0.8
Gender
Men 56% (45) 74% (236) 0.01
Women 44% (35) 26% (84)
Race/Ethnicity
0.1
African American 63% (50) 73% (234)
Black Caribbean 3% (2) 2% (6)
Hispanic 27% (22) 20% (64)
White 7% (6%) 5% (16)
Education (years of school) 11.6 ± 2.3 11.3 ± 2.3 0.2
Years Living with HIV 14.9 ± 7.5 15.6 ± 8 0.6
Mode of HIV Transmission
0.2
Homosexual 59% 51%
Heterosexual 30% 26%
Drugs 3% 8%
Transfusion 4% 8%
Multiple risks of Exposure 4% 7%
Years drinking 6.6 ± 1.2 8.8 ± 0.6 0.1
Total number of drinks per week 15 ± 1.3 19 ± 3.5 0.04
Albumin mg/dl 4 ± 0.6 4.2 ± 0.5 0.9
Liver enzymes
AST IU/L 35 ± 20 41 ± 23 0.06
ALT IU/L 33 ± 30 38 ± 27 0.3
Antiretroviral Therapy 94% 93% 0.5
Adherence (ACTG) 86% 88% 0.5
Mood disorders treatment 32% 37% 0.2
Note. Values are means ± SD or percentages with exact n in the parenthesis.
Note. Significant drinking and gender differences were found between groups.
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Table 3
Multivariate analyses of predictors of undetectable viral loads in subjects receiving antiretroviral therapy.
Parameter OR 95% Confidence Interval
Lower Upper Sig.
CD4 Counts <500 0.322 -112.302 -45.654 0.000
Binge Drinking 0.335 1.211 7.96 0.047
No-TCP 8.7 5.50 11.301 0.000
High Serotonin 5.479 2.504 11.991 0.05
Partition for the Hosmer and Leme show Test (p=0.26).
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Table 4
Multivariate Analyses for CD4 counts above 500 at the last visit.
Variables OR Significance 95% CI Lower Bound 95% CI Upper Bound
Viral Load undetectable 17.772 0.000 4.964 63.626
Gender 3.80 0.001 2.1 7.39
No Binge Drinkers 1.939 0.026 1.689 4.908
Partition for the Hosmer and Leme show Test (p=0.8).
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